CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma

被引:10
作者
Chu, Bin [1 ]
Bao, Li [1 ]
Wang, Yutong [1 ]
Lu, Minqiu [1 ]
Shi, Lei [1 ]
Gao, Shan [1 ]
Fang, Lijuan [1 ]
Xiang, Qiuqing [1 ]
Liu, Xi [1 ]
机构
[1] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China
基金
北京市自然科学基金;
关键词
Multiple myeloma; CD27; antigen; Overall survival; Cytogenetic; Gene mutation; MULTIPARAMETRIC FLOW-CYTOMETRY; MINIMAL RESIDUAL DISEASE; CLINICAL-SIGNIFICANCE; CEREBLON EXPRESSION; SURVIVAL; IDENTIFICATION; PREDICTION; MUTATIONS; CONSENSUS; SPECTRUM;
D O I
10.1016/j.clim.2020.108363
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To investigate the role of CD27 in multiple myeloma(MM), bone marrow samples from 165 newly diagnosed MM were analysed by flow cytometry. CD27- group (n = 93) had higher level of plasma cell proportion (37.00% vs 22.50%, p < .05), beta 2-MG (5.42 vs 3.20 mg/L, p < .05), calcium (2.45 vs 2.28 mmol/L, p < .05),higher percentage of ISS stage III (49.46% vs 22.22%, p < .05) and patients with >= 2 high-risk cytogenetics (24.73% vs 15.28%, p < .05) than CD27+ group (n = 72). After 4 cycles of chemotherapy, the overall response rate in CD27- group were lower than CD27+ group (56.67% vs 73.02%, p < .05). After a median follow-up of 18 months, progression-free survival was significantly shorter in CD27- group than in CD27+ group (22 vs 40 months, p < .05), so was overall survival (median OS not reached, p < .05). Gene sequencing showed more adverse mutations in CD27- group than CD27+ group.
引用
收藏
页数:8
相关论文
共 33 条
[1]   CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma [J].
Alaterre, Elina ;
Raimbault, Sebastien ;
Goldschmidt, Hartmut ;
Bouhya, Salahedine ;
Requirand, Guilhem ;
Robert, Nicolas ;
Boireau, Stephanie ;
Seckinger, Anja ;
Hose, Dirk ;
Klein, Bernard ;
Moreaux, Jerome .
ONCOTARGET, 2017, 8 (58) :98931-98944
[2]   Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines [J].
Anderson, Kenneth C. ;
Alsina, Melissa ;
Atanackovic, Djordje ;
Biermann, J. Sybil ;
Chandler, Jason C. ;
Costello, Caitlin ;
Djulbegovic, Benjamin ;
Fung, Henry C. ;
Gasparetto, Cristina ;
Godby, Kelly ;
Hofmeister, Craig ;
Holmberg, Leona ;
Holstein, Sarah ;
Huff, Carol Ann ;
Kassim, Adetola ;
Krishnan, Amrita Y. ;
Kumar, Shaji K. ;
Liedtke, Michaela ;
Lunning, Matthew ;
Raje, Noopur ;
Reu, Frederic J. ;
Singhal, Seema ;
Somlo, George ;
Stockerl-Goldstein, Keith ;
Treon, Steven P. ;
Weber, Donna ;
Yahalom, Joachim ;
Shead, Dorothy A. ;
Kumar, Rashmi .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (04) :389-400
[3]   Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials [J].
Arana, P. ;
Paiva, B. ;
Cedena, M-T ;
Puig, N. ;
Cordon, L. ;
Vidriales, M-B ;
Gutierrez, N. C. ;
Chiodi, F. ;
Burgos, L. ;
Anglada, L-L ;
Martinez-Lopez, J. ;
Hernandez, M-T ;
Teruel, A-I ;
Gironella, M. ;
Echeveste, M-A ;
Rosinol, L. ;
Martinez, R. ;
Oriol, A. ;
De la Rubia, J. ;
Orfao, A. ;
Blade, J. ;
Lahuerta, J-J ;
Mateos, M-V ;
San Miguel, J-F .
LEUKEMIA, 2018, 32 (04) :971-978
[4]   Immunophenotypic Characterization and Quantification of Neoplastic Bone Marrow Plasma Cells by Multiparametric Flow Cytometry and Its Clinical Significance in Korean Myeloma Patients [J].
Cho, Young-Uk ;
Park, Chan-Jeoung ;
Park, Seo-Jin ;
Chi, Hyun-Sook ;
Jang, Seongsoo ;
Park, Sang Hyuk ;
Seo, Eul-Ju ;
Yoon, Dok Hyun ;
Lee, Jung-Hee ;
Suh, Cheolwon .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (04) :542-549
[5]   International staging system for multiple myeloma [J].
Greipp, PR ;
San Miguel, J ;
Durie, BGM ;
Crowley, JJ ;
Barlogie, B ;
Bladé, J ;
Boccadoro, M ;
Child, JA ;
Harousseau, JL ;
Kyle, RA ;
Lahuerta, JJ ;
Ludwig, H ;
Morgan, G ;
Powles, R ;
Shimizu, K ;
Shustik, C ;
Sonneveld, P ;
Tosi, P ;
Turesson, I ;
Westin, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420
[6]   High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes [J].
Hu, Bei ;
Thall, Peter ;
Milton, Denai R. ;
Sasaki, Koji ;
Bashir, Qaiser ;
Shah, Nina ;
Patel, Krina ;
Popat, Uday ;
Hosing, Chitra ;
Nieto, Yago ;
Lin, Pei ;
Delgado, Ruby ;
Jorgensen, Jeffrey ;
Manasanch, Elisabet ;
Weber, Donna ;
Thomas, Sheeba ;
Orlowski, Robert Z. ;
Champlin, Richard ;
Qazilbash, Muzaffar H. .
LEUKEMIA & LYMPHOMA, 2019, 60 (02) :442-452
[7]  
Katayama Y., 2003, BRIT J HAEMATOL, V120, P556
[8]   Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients [J].
Kortuem, K. M. ;
Braggio, E. ;
Bruins, L. ;
Barrio, S. ;
Shi, C. S. ;
Zhu, Y. X. ;
Tibes, R. ;
Viswanatha, D. ;
Votruba, P. ;
Ahmann, G. ;
Fonseca, R. ;
Jedlowski, P. ;
Schlam, I. ;
Kumar, S. ;
Bergsagel, P. L. ;
Stewart, A. K. .
BLOOD CANCER JOURNAL, 2016, 6
[9]   Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes [J].
Kortum, K. Martin ;
Mai, Elias K. ;
Hanafiah, Nur H. ;
Shi, Chang-Xi ;
Zhu, Yuan-Xiao ;
Bruins, Laura ;
Barrio, Santiago ;
Jedlowski, Patrick ;
Merz, Maximilian ;
Xu, Jing ;
Stewart, Robert A. ;
Andrulis, Mindaugas ;
Jauch, Anna ;
Hillengass, Jens ;
Goldschmidt, Hartmut ;
Bergsagel, P. Leif ;
Braggio, Esteban ;
Stewart, A. Keith ;
Raab, Marc S. .
BLOOD, 2016, 128 (09) :1226-1233
[10]   Lack of CD27 in myeloma delineates different presentation and outcome [J].
Moreau, P ;
Robillard, N ;
Jégo, G ;
Pellat, C ;
Le Gouill, S ;
Thoumi, S ;
Avet-Loiseau, H ;
Harousseau, JL ;
Bataille, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (02) :168-170